Cure Parkinson’s is delighted to be supporting two sub-studies within the Bydureon (exenatide) phase 3 trial which is recruiting from six sites in the UK.
This phase 3 clinical trial is testing the efficacy of exenatide in a large cohort of people with Parkinson’s and is the next stage in a programme of trials and research studies to determine whether this GLP-1 diabetes drug is a beneficial treatment.
This two year study involves 200 people with Parkinson’s taking place in six sites around the UK.
We want the criteria for inclusion in this trial to be as broad as possible, so that the results are relevant to the majority of people with Parkinson’s and not just a small sub-group.
Professor Tom Foltynie, Principal Investigator, UCL
